XXEC Inc. Takes Position in Heartflow, Inc. $HTFL

XXEC Inc. purchased a new position in shares of Heartflow, Inc. (NASDAQ:HTFL) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 77,270,845 shares of the company’s stock, valued at approximately $2,524,764,000. Heartflow accounts for about 1.3% of XXEC Inc.’s holdings, making the stock its 5th biggest position. XXEC Inc. owned 0.90% of Heartflow as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new stake in Heartflow during the fourth quarter valued at approximately $27,000. Russell Investments Group Ltd. acquired a new position in shares of Heartflow in the 4th quarter worth approximately $45,000. Legal & General Group Plc bought a new stake in shares of Heartflow in the 3rd quarter valued at approximately $59,000. Essential Partners LLC bought a new stake in shares of Heartflow in the 1st quarter valued at approximately $57,000. Finally, Strs Ohio acquired a new stake in shares of Heartflow during the 4th quarter valued at approximately $99,000.

Heartflow Price Performance

NASDAQ:HTFL opened at $49.75 on Friday. Heartflow, Inc. has a 12-month low of $20.13 and a 12-month high of $50.48. The firm has a market capitalization of $4.33 billion and a P/E ratio of -27.19. The business has a 50 day simple moving average of $30.66 and a 200 day simple moving average of $28.32.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. The firm had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The business’s quarterly revenue was up 47.7% on a year-over-year basis. Research analysts anticipate that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on HTFL shares. Morgan Stanley lifted their price objective on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Weiss Ratings raised shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Robert W. Baird set a $45.00 price target on shares of Heartflow in a research report on Friday, August 14th. Benchmark reaffirmed a “buy” rating on shares of Heartflow in a research report on Friday, August 14th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.43.

Insider Activity

In related news, CEO John C.M. Farquhar sold 38,900 shares of Heartflow stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total value of $1,361,500.00. Following the sale, the chief executive officer directly owned 457,935 shares in the company, valued at $16,027,725. This trade represents a 7.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $41.23, for a total transaction of $380,099.37. Following the transaction, the insider directly owned 86,459 shares of the company’s stock, valued at $3,564,704.57. The trade was a 9.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 164,041 shares of company stock valued at $5,727,636 in the last 90 days. Insiders own 7.70% of the company’s stock.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.